Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Zentalis Pharmaceuticals	Madrigal Pharmaceuticals	NGM Biopharmaceuticals	Axsome Therapeutics	Amarin
Symbol	NASDAQ:ZNTL	NASDAQ:MDGL	NASDAQ:NGM	NASDAQ:AXSM	NASDAQ:AMRN
Price Information
Current Price	$58.82	$134.70	$28.58	$58.42	$4.38
52 Week Range	Buy	Buy	Buy	Buy	Hold
MarketRank™
Overall Score	1.4	1.5	1.7	1.6	1.6
Analysis Score	1.5	2.4	3.6	3.4	3.2
Community Score	3.3	2.8	3.4	2.7	3.1
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	2.5	1.7	1.7	0.8
Earnings & Valuation Score	0.6	0.0	0.0	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Hold
Consensus Price Target	$62.60	$167.60	$39.11	$133.83	$10.50
% Upside from Price Target	6.43% upside	24.42% upside	36.85% upside	129.09% upside	139.73% upside
Trade Information
Market Cap	$2.43 billion	$2.23 billion	$2.20 billion	$2.19 billion	$1.72 billion
Beta	N/A	1.19	1.97	2.59	2.58
Average Volume	297,746	162,137	255,723	342,305	6,371,316
Sales & Book Value
Annual Revenue	N/A	N/A	$103.54 million	N/A	$429.76 million
Price / Sales	N/A	N/A	21.26	N/A	4.01
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	N/A	$27.00 per share	$4.96 per share	$5.18 per share	$1.63 per share
Price / Book	N/A	N/A	5.76	N/A	2.69
Profitability
Net Income	N/A	$-83,950,000.00	$-42,790,000.00	$-68,350,000.00	$-22,650,000.00
EPS	N/A	($5.45)	($0.85)	($2.01)	($0.07)
Trailing P/E Ratio	0.00	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	36.50
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	-91.64%	N/A	-2.69%
Return on Equity (ROE)	N/A	-47.64%	-29.47%	-62.33%	-2.70%
Return on Assets (ROA)	N/A	-43.21%	-25.58%	-47.87%	-1.72%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	0.36%	N/A
Current Ratio	N/A	6.84%	8.01%	9.99%	2.72%
Quick Ratio	N/A	6.84%	8.01%	9.99%	2.27%
Ownership Information
Institutional Ownership Percentage	67.13%	74.24%	49.56%	63.64%	37.78%
Insider Ownership Percentage	N/A	41.89%	50.40%	26.00%	2.75%
Miscellaneous
Employees	124	42	210	60	1,000
Shares Outstanding	41.31 million	16.59 million	77.02 million	37.57 million	393.44 million
Next Earnings Date	5/21/2021 (Estimated)	8/5/2021 (Estimated)	8/11/2021 (Estimated)	8/9/2021 (Estimated)	8/3/2021 (Estimated)
Optionable	Not Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl) - GlobeNewswire globenewswire.com - May 15 at 8:36 AM
	REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology’s 70th Annual Scientific Session finance.yahoo.com - May 15 at 8:36 AM
	Why Amarin Stock Is Tumbling Today - Motley Fool fool.com - May 12 at 3:42 PM
	Why Amarin Stock Is Tumbling Today finance.yahoo.com - May 12 at 3:41 PM
	Amarin (NASDAQ:AMRN) Shares Gap Down to $4.61 americanbankingnews.com - May 12 at 11:50 AM
	Novavax downgraded at JP Morgan on vaccine timeline, Amarin cut to sell at Goldman Sachs; in today’s analyst action - Seeking Alpha seekingalpha.com - May 12 at 10:41 AM
	Amarin Corporation plc (AMRN) Down 4.56% in Premarket Trading - InvestorsObserver investorsobserver.com - May 12 at 10:41 AM
	Amarin (NASDAQ:AMRN) Rating Lowered to Sell at The Goldman Sachs Group americanbankingnews.com - May 12 at 8:22 AM
	Amarin (NASDAQ:AMRN) Lowered to "Sell" at The Goldman Sachs Group marketbeat.com - May 12 at 7:21 AM
	Patents Are Personal - Above the Law abovethelaw.com - May 11 at 6:34 PM
	Amarin Corporation Plc (NASDAQ:AMRN) Will Commercialize VAZKEPA In Q3 2021: Reports Revenues Of $142.2 Million In Q2 2021 - BP Journal biopharmajournal.com - May 7 at 10:42 AM
	Brokers Set Expectations for Amarin Co. plc's FY2022 Earnings (NASDAQ:AMRN) americanbankingnews.com - May 6 at 11:42 AM
	Amarin PLC Stock Appears To Be Possible Value Trap - Yahoo Finance finance.yahoo.com - May 5 at 4:38 PM
	Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific Session - Yahoo Finance finance.yahoo.com - May 5 at 12:03 AM
	Relative Strength Alert For Amarin - Nasdaq nasdaq.com - May 5 at 12:03 AM
	Is Amarin Corporation plc (AMRN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver investorsobserver.com - May 4 at 1:51 PM
	Clinical Data and Other Research Results Regarding VASCEPA® - GlobeNewswire globenewswire.com - May 4 at 8:50 AM
	Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific Session finance.yahoo.com - May 4 at 8:50 AM
	-$0.04 Earnings Per Share Expected for Amarin Co. plc (NASDAQ:AMRN) This Quarter americanbankingnews.com - May 3 at 10:22 AM
	Amarin Searches For New GC As Top Lawyer Plans To Retire - Law360 law360.com - April 30 at 8:24 PM
	Dr Reddy's Accuses Amarin Of 'Illegally' Blocking Vascepa API Supply - Generics Bulletin generics.pharmaintelligence.informa.com - April 30 at 3:23 PM
	Analysts Offer Insights on Healthcare Companies: Amarin (AMRN) and Mirum Pharmaceuticals (MIRM) - Smarter Analyst smarteranalyst.com - April 30 at 10:22 AM
	Should You Buy Amarin Corporation plc (AMRN) Stock After it Is Up 3.85% in a Week? - InvestorsObserver investorsobserver.com - April 29 at 11:59 PM
	Amarin (AMRN) Q1 2021 Earnings Call Transcript - The Motley Fool fool.com - April 29 at 11:59 PM
	Amarin (AMRN) Q1 2021 Earnings Call Transcript finance.yahoo.com - April 29 at 11:59 PM
	Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19 - Yahoo Finance finance.yahoo.com - April 29 at 6:59 PM

Date	Company	Brokerage	Action
4/19/2021	Zentalis Pharmaceuticals	SVB Leerink	Boost Price Target
4/1/2021	Zentalis Pharmaceuticals	HC Wainwright	Boost Price Target
1/19/2021	Zentalis Pharmaceuticals	Wedbush	Initiated Coverage
12/16/2020	Zentalis Pharmaceuticals	Morgan Stanley	Boost Price Target
9/28/2020	Zentalis Pharmaceuticals	Cantor Fitzgerald	Initiated Coverage
4/28/2020	Zentalis Pharmaceuticals	Guggenheim	Initiated Coverage
4/28/2020	Zentalis Pharmaceuticals	Jefferies Financial Group	Initiated Coverage
3/4/2021	Madrigal Pharmaceuticals	Chardan Capital	Boost Price Target
3/2/2021	Madrigal Pharmaceuticals	Oppenheimer	Lower Price Target
11/23/2020	Madrigal Pharmaceuticals	Evercore ISI	Reiterated Rating
11/12/2020	Madrigal Pharmaceuticals	Canaccord Genuity	Lower Price Target
11/6/2020	Madrigal Pharmaceuticals	The Goldman Sachs Group	Boost Price Target
11/6/2020	Madrigal Pharmaceuticals	BMO Capital Markets	Boost Price Target
11/5/2020	Madrigal Pharmaceuticals	Piper Sandler	Lower Price Target
8/6/2020	Madrigal Pharmaceuticals	Stifel Nicolaus	Reiterated Rating
5/22/2020	Madrigal Pharmaceuticals	B. Riley	Boost Price Target
3/5/2020	Madrigal Pharmaceuticals	Citigroup	Lower Price Target
3/11/2021	NGM Biopharmaceuticals	Raymond James	Boost Price Target
12/21/2020	NGM Biopharmaceuticals	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target
12/21/2020	NGM Biopharmaceuticals	Smith Barney Citigroup	Boost Price Target
3/23/2020	NGM Biopharmaceuticals	Cowen	Reiterated Rating
5/12/2021	Axsome Therapeutics	BTIG Research	Reiterated Rating
3/2/2021	Axsome Therapeutics	Mizuho	Lower Price Target
12/31/2020	Axsome Therapeutics	UBS Group	Reiterated Rating
10/1/2020	Axsome Therapeutics	William Blair	Reiterated Rating
9/29/2020	Axsome Therapeutics	Bank of America	Initiated Coverage
4/27/2020	Axsome Therapeutics	LADENBURG THALM/SH SH	Boost Price Target
4/27/2020	Axsome Therapeutics	SunTrust Banks	Boost Price Target
9/29/2020	Amarin	JPMorgan Chase & Co.	Initiated Coverage
5/5/2020	Amarin	Northland Securities	Initiated Coverage
5/4/2020	Amarin	Aegis	Boost Price Target

(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources